Oncocyte Corp financial data

Symbol
OCX on Nasdaq
Location
15 Cushing, Irvine, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 10, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 308 % +206%
Quick Ratio 6.5 %
Debt-to-equity -1.97K % -688%
Return On Equity 2.39K %
Return On Assets -128 % -116%
Operating Margin -1.39K % +77.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 28.7M shares +70.3%
Common Stock, Shares, Outstanding 28.6M shares +114%
Entity Public Float 24.6M USD +30.9%
Common Stock, Value, Issued 369M USD +12.8%
Weighted Average Number of Shares Outstanding, Basic 32M shares +134%
Weighted Average Number of Shares Outstanding, Diluted 32M shares +134%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 4.4M USD +521%
Cost of Revenue 1.96M USD +231%
Research and Development Expense 12.3M USD +21.8%
Selling and Marketing Expense 5.25M USD +58.1%
General and Administrative Expense 10.9M USD +15.6%
Operating Income (Loss) -61.3M USD -40.7%
Nonoperating Income (Expense) 538K USD +19.8%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -60.7M USD -144%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -60.8M USD -40.9%
Earnings Per Share, Basic -3 USD/shares +34.8%
Earnings Per Share, Diluted -3 USD/shares +34.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 18.7M USD +456%
Accounts Receivable, after Allowance for Credit Loss, Current 258K USD +23.4%
Inventory, Net 471K USD +103%
Assets, Current 21.4M USD +346%
Property, Plant and Equipment, Net 5.8M USD -6.31%
Operating Lease, Right-of-Use Asset 4.04M USD +15.3%
Intangible Assets, Net (Excluding Goodwill) 14.6M USD -74.2%
Other Assets, Noncurrent 672K USD -3.86%
Assets 43.9M USD -37.4%
Accounts Payable, Current 1.06M USD +21.1%
Accrued Liabilities, Current 2.23M USD +16.9%
Liabilities, Current 7.66M USD -15.7%
Liabilities 53.1M USD -12.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax 86K USD +50.9%
Retained Earnings (Accumulated Deficit) -378M USD -19.2%
Stockholders' Equity Attributable to Parent -9.2M USD -195%
Liabilities and Equity 43.9M USD -37.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -5.86M USD -53%
Net Cash Provided by (Used in) Financing Activities 28.6M USD
Net Cash Provided by (Used in) Investing Activities -307K USD -1179%
Common Stock, Shares Authorized 230M shares 0%
Common Stock, Shares, Issued 28.6M shares +114%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 22.4M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 19.1M USD -59%
Interest Paid, Excluding Capitalized Interest, Operating Activities 24K USD
Deferred Tax Assets, Valuation Allowance 64.4M USD -4.28%
Deferred Tax Assets, Gross 69.1M USD -16.4%
Operating Lease, Liability 1.95M USD -31.1%
Depreciation 450K USD +56.8%
Payments to Acquire Property, Plant, and Equipment 307K USD +1179%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -60.7M USD -40.9%
Lessee, Operating Lease, Liability, to be Paid 2.17M USD -34.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two 696K USD -41.1%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.18M USD +3.32%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 213K USD -54.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 0 USD -100%
Deferred Tax Assets, Operating Loss Carryforwards 50M USD -19.1%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 1.1M USD -52.2%
Lessee, Operating Lease, Liability, to be Paid, Year Four 695K USD -22.7%
Operating Lease, Payments 281K USD +3.31%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets 29K USD -67%
Depreciation, Depletion and Amortization 2.2M USD +71.8%
Deferred Tax Assets, Net of Valuation Allowance 4.68M USD -69.5%
Share-based Payment Arrangement, Expense 2M USD +14.9%